- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
PFE
GER
Week ended 31 Jul 2026
Weekly Investor Report
Pfizer Inc. · Healthcare · Drug Manufacturers - General
Latest close
21.71 EUR
0.4%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -1.9% below the Trend Line and sits at 50.1% of its 52-week range. The latest completed week returned 0.4%, after a 3.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.
Setup score
49
out of 100
Latest Close
21.71 EUR
31 Jul 2026
1W Return
0.4%
latest completed week
4W Return
3.5%
short-term follow-through
12W Return
-1.0%
quarterly tape
Trend Breadth
73.1%
38 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.4%
Latest completed week; four-week move 3.5%.
Indicator stack
40/39
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
34 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.9% below the Trend Line and sits at 50.1% of its 52-week range. The latest completed week returned 0.4%, after a 3.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2812-week average 0.46
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 3.5% over four weeks, -1.0% over 12 weeks, and 14.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year38
Trend breadth73.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.77Latest activity-pressure read.
Pressure change33.2%Four-week change in activity pressure.
Leadership-3.91Latest relative-leadership reading.
RS change47.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 90%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength83/100Blend of value, momentum, and quality. Underlying universe rank 18; rank 1 is best.
Value71/100Relative valuation strength. Underlying universe rank 30; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth18/100Revenue and earnings growth. Underlying universe rank 83; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework82/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 16.5x Price divided by trailing earnings.
- Price / sales
- 1.9x Market value relative to trailing revenue.
- EV / EBITDA
- 10.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 5.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 73.5% Gross profit retained from each unit of revenue.
- Operating margin
- 27.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 15.0% Free cash flow generated from revenue.
- Return on invested capital
- 8.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -1.6% Latest one-year revenue growth.
- EPS growth
- -3.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -7.7% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 7.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 7.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 34 relevant articles.
8 positive · 19 neutral · 7 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-11.1%Distance below the 52-week high.
13-week volatility2.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher13 of 2612 weeks finished lower.
Best week+4.4%Week of 6 Feb.
Worst week-6.9%Week of 10 Apr.
Latest week+0.4%Week of 31 Jul.
Shape of recent returns
Strong gains3
Modest gains10
Flat weeks1
Modest losses9
Sharp losses3
Recent vol2.2%13-week weekly-return volatility.
Base vol3.4%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew2.4% / -2.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank27 / 78
Group average-0.2%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD67.9%positive activity pressure
RS37.2%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - General
4-week rank3 / 12
Group average-1.0%
Trend breadth58.3%
Trend58.3%active weekly trend signals
MD83.3%positive activity pressure
RS75.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape46/100
Trend, activity pressure, participation, and risk combine to a 46/100 tape read.
Indicator analysis34/100Latest 12-week confirmation: trend 6/12, activity pressure 0/12, relative leadership 5/12.
Activity pressure 0.28; No reversal markers Factors70/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 75 SVQF82/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 68.0 of 372 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 34 relevant articles.
Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 21.71 EUR | 0.4% | 22.14 EUR | 21.89 EUR | -0.77 | -3.91 | 161.6K | Off |
| 24 Jul 2026 | 21.63 EUR | -0.2% | 22.11 EUR | 21.92 EUR | -0.92 | -2.18 | 139.3K | Off |
| 17 Jul 2026 | 21.68 EUR | 4.2% | 22.07 EUR | 21.96 EUR | -1.08 | -0.82 | 228.1K | Off |
| 10 Jul 2026 | 20.80 EUR | -0.8% | 22.04 EUR | 21.99 EUR | -1.26 | -5.58 | 181.9K | Off |
| 3 Jul 2026 | 20.97 EUR | 0.6% | 22.06 EUR | 22.03 EUR | -1.15 | -7.43 | 181.9K | Off |
| 26 Jun 2026 | 20.85 EUR | -3.7% | 22.07 EUR | 22.06 EUR | -1.09 | -3.89 | 55.6K | Off |
| 19 Jun 2026 | 21.65 EUR | -4.4% | 22.09 EUR | 22.10 EUR | -0.96 | -1.36 | 11.5K | On |
| 12 Jun 2026 | 22.64 EUR | 0.0% | 22.07 EUR | 22.15 EUR | -0.90 | 4.75 | 20.5K | On |
| 5 Jun 2026 | 22.64 EUR | 1.8% | 22.01 EUR | 22.19 EUR | -0.96 | 4.41 | 33.5K | On |
| 29 May 2026 | 22.24 EUR | -0.3% | 21.93 EUR | 22.24 EUR | -0.88 | 1.40 | 132.6K | On |
| 22 May 2026 | 22.30 EUR | 2.3% | 21.86 EUR | 22.28 EUR | -0.77 | 2.78 | 176.8K | On |
| 15 May 2026 | 21.80 EUR | -0.6% | 21.79 EUR | 22.32 EUR | -0.63 | 4.63 | 223.6K | On |
| 8 May 2026 | 21.94 EUR | -1.9% | 21.72 EUR | 22.36 EUR | -0.36 | 3.90 | 334.0K | On |
| 1 May 2026 | 22.36 EUR | -0.2% | 21.66 EUR | 22.40 EUR | -0.05 | 6.37 | 236.7K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.